Inovio Finalizes $80.5M Net Raise as Underwriters Take Full Option
INO has more than doubled off its 52-week low of $0.563 on elevated volume (3.8× avg).
Summary
Inovio closed the books on its underwritten offering at $1.05 per share, with the full option exercised for about $80.5 million net — enough, management says, to fund operations into late fourth quarter 2027.
Key Events · Financing and Capital Events · INO
-
Offering Priced at $1.05, Option Fully Exercised
58,747,235 shares at $1.05 plus pre-funded warrants for 12,681,337 shares at $1.049; underwriters exercised the full 10,714,285-share option on November 6, 2026.
-
Net Proceeds of About $80.5 Million
Expected net proceeds are approximately $80.5 million after underwriting discounts and estimated offering expenses, versus roughly $75 million gross on the base deal.
-
Runway Extended to Late Q4 2027
Management states net proceeds plus current cash, cash equivalents and short-term investments fund operating expenses and capital expenditure requirements into late fourth quarter 2027.
-
Deep Discount to Pre-Launch Price
The $1.05 offering price compares with a $1.45 last reported sale before launch, a roughly 28% discount that shifts value to new buyers.
Analysis · INO · Life Sciences
Inovio locked in roughly $80.5 million net from its underwritten offering after Jefferies, Piper Sandler and H.C. Wainwright exercised the full 10,714,285-share option on November 6, 2026. The cash matters more than the mechanics: the company entered the year with a going-concern warning and runway only into late Q1 2027, and management now says proceeds plus existing cash fund operations into late fourth quarter 2027 — roughly three extra quarters of life. The price is the cost: shares and pre-funded warrants were sold at $1.05 and $1.049, against a $1.45 last reported sale before launch, so buyers got a steep discount and existing holders absorbed heavy dilution. The 90-day company lock-up and director/officer lock-ups limit further supply near term, but the overhang from 71.4 million new shares plus 12.7 million warrant shares is now a fixed part of the capital structure.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.6M. The 52-week trading range was $0.56 to $2.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.